Navigation Links
Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Date:12/7/2007

a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which is in a Phase 1 clinical trial in advanced cancer patients; RDEA806 for gout, which is expected to enter a Phase 2 efficacy trial in the first half of 2008. Ardea also is developing a next-generation NNRTI and a next-generation MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of having active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases in the first half of 2008, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the ... the opportunities for advanced analytics utilizing data lakes in the healthcare industry. , As ... seen an explosion of data over the last few years as more entities become ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted by ... Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer Research, and ... first multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, and ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million. The orders are for air emission abatement projects in ... is a large order for a municipality in the ... replacing a competitor,s system that failed to meet the customer,s ... solutions," said Derek S. Webb , President and Chief ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.20 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Mexico Biomedical Sensors Market Report 2015-2020 2
... ground-breaking treatment option for victims of whiplash associated disorders (WAD). ... Z Therapy is the first and only rehabilitation specialist in North ... neck pain. , ... Dallas, TX (PRWEB) April 21, ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets.NxStage will also ... on Friday, May 8, 2009 to discuss its first ...
... LLC announced today that it has issued an Executive ... 56-page report can be found at www.crystalra.com ... is a closely held pharmaceutical company focused exclusively on ... a technology spinout from Bayer HealthCare LLC, ACT Biotech ...
Cached Biology Technology:Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers 2NxStage to Report First Quarter 2009 Financial Results 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... the most abundant biomass material on Earth, and therefore ... for the production of advance biofuels. A major roadblock, ... Researchers with the U.S. Department of Energy (DOE),s Joint ... removing this roadblock by identifying a gene in rice ...
... experts from around the world in Clinical Rehabilitation, Applied ... to 16th, at the First International Conference on NeuroRehabilitation ... conference, organized in Toledo (Spain) by researchers of the ... state of the therapies that are currently being conducted ...
... 2012) John Wiley & Sons, Inc., (NYSE:JWa, JWb), ... areas of scientific, technical, medical, and scholarly research; professional ... TED, the non-profit devoted to Ideas Worth Spreading, to ... series of "TED Studies." To support the ...
Cached Biology News:A better route to xylan 2A better route to xylan 3Leader experts in neurorehabilitation gather in Toledo, Spain 2Wiley Partners with TED 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: